NCT03027193View on ClinicalTrials.gov

A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

January 16, 2020

Study Completion Date

January 16, 2020

Conditions
Crohn DiseaseMycobacterium Avium Subspecies Paratuberculosis
Interventions
BIOLOGICAL

ChAdOx2 HAV

The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens

BIOLOGICAL

MVA HAV

The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.

Trial Locations (1)

Unknown

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03027193 - A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter